B3 · Pillar B · Spending Efficiency
Prescription drug negotiation expansion
Expand IRA Medicare drug-price negotiation from the current catalog to a substantially broader set over five years, including biologics, and extend negotiated prices to Medicaid, the VA, and (through reference pricing) commercial markets.
- 10-year fiscal
- −$650BSavings
- Implementation
- Years 1–5
- Middle class
- Positive
- Planetary
- Neutral
$500B–$800B · Medium-High confidence
Substantial reductions in out-of-pocket prescription costs across covered populations.
No material climate effect.
Global precedent
Germany’s AMNOG (2011) produced about 24.5 percent average price reductions on negotiated drugs. The IRA’s first U.S. round achieved 38–79 percent reductions on the initial ten high-cost drugs.
Lead mechanism
CMS; HHS.
Bipartisan framing
Conservative case
Brings market discipline to a price-insensitive segment; rewards true clinical innovation.
Progressive case
Addresses U.S.–international price differentials of 200–400 percent on identical drugs.
Figures in this framework are illustrative directional estimates derived from publicly available data and conventional Congressional Budget Office budget-window logic. They are not official CBO scores. Any provision adopted from this framework would require formal CBO scoring before legislative consideration. This document is a policy white paper, not an introduced bill.